News & Updates

Orbis International Welcomes New Members to its Board of Directors

Orbis welcomes Dr. Pravin Dugel, managing partner, Retinal Consultants of Arizona, and David Gitlin, President, UTC Aerospace Systems, to its Board of Directors. Pravin has been involved with Orbis since 2010 as a member of our Volunteer Faculty, specializing in retinal diseases including diabetic retinopathy. “I am extremely honored to join the Orbis Board of… Read More »

Dr. Pravin Dugel – Highlights from Day 1 of Retina Subspecialty Day 2017Findings from neovascular AMD studies a highlight from Day 1

Findings from neovascular AMD studies a highlight from Day 1 NEW ORLEANS – The 48-week results of the HAWK and HARRIER studies on brolucizumab (Novartis) for the treatment of neovascular age-related macular degeneration (AMD) were one of the highlights from Day 1 at Retina Subspecialty Day. Pravin Dugel, MD, (Phoenix, Ariz.) first described the antibody… Read More »

Novartis’ eye drug clearly works, but edging out Eylea won’t be easy – Dr. Pravin U. Dugel

Dive Brief: Novartis AG’s investigational eye drug bested Regeneron Pharmaceutical Inc.’s Eylea on additional secondary endpoints of two late-stage studies, bolstering the treatment’s potential to go head to head with Regeneron’s market leader. In HAWK trial, 35% fewer patients had intra-retinal fluid (IRF) and/or sub-retinal fluid (SRF) after 16 weeks of taking Novartis’ brolucizumab 6 mg versus… Read More »

Novartis’ VEGF inhibitor demonstrates clinically relevant anatomic, visual gains – Dr. Pravin Dugel

MEETING NEWS American Academy of Ophthalmology Meeting NEW ORLEANS — Novartis’ first-in-kind molecule brolucizumab achieved clinically relevant anatomic and visual acuity gains in patients with age-related macular degeneration with every-12-week dosing, according to a speaker. Two dosages of the single-chain antibody fragment VEGF inhibitor were compared with Eylea (aflibercept, Regeneron) in two phase 3 trials,… Read More »

Dr. Derek Kunimoto First in Arizona to Use B&L’s New Bi-Blade Cutter, Vitrectomy Procedure

Retinal Consultants of Arizona and the Retina Research Institute is dedicated to providing the most advanced, personalized patient care in Arizona. Our practice is at the forefront of implementing the latest technologies available for the diagnosis, management and treatment of retina and vitreous disease and conditions – all designed for the highest quality patient care… Read More »


Phoenix – December 8th, 2017 – On Monday, November 13th during the Society Presidents’ Recognition and Awards Session held in conjunction with AAO 2017 in New Orleans, Dr. Derek Y. Kunimoto was recognized for completing his participation in the Academy’s Leadership Development Program XIXI, Class of 2017.   Dr. Kunimoto was among a select group of… Read More »

Dr. Pravin Dugel: “Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness”

Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness  Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept  Significantly… Read More »

Spectra Eye Institute Opens Second Location at Retinal Consultants of Arizona – North Phoenix

Phoenix – October 15th, 2017 – Spectra Eye Institute – a leading, private outpatient surgical center dedicated to comprehensive ophthalmic surgical care – has opened its North Phoenix location inside the new Retinal Consultants of Arizona North Phoenix facility at Greenway and the I-17. The new 9,200 square foot surgical facility is set up for… Read More »